PT - JOURNAL ARTICLE AU - A Braun AU - M M Mouradian AU - E Mohr AU - G Fabbrini AU - T N Chase TI - Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. AID - 10.1136/jnnp.52.5.631 DP - 1989 May 01 TA - Journal of Neurology, Neurosurgery & Psychiatry PG - 631--635 VI - 52 IP - 5 4099 - http://jnnp.bmj.com/content/52/5/631.short 4100 - http://jnnp.bmj.com/content/52/5/631.full SO - J Neurol Neurosurg Psychiatry1989 May 01; 52 AB - The motor and cognitive effects of a selective D-1 dopamine receptor agonist, SKF 39393, were assessed in patients with Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, and torsion dystonia, using a double-blind placebo-controlled design. Over daily doses ranging from 3.2 to 32 mg/kg and treatment intervals extending from one to seven weeks, no consistent changes could be discerned. The contribution of D-1 receptor mediated mechanisms to the pathophysiology of hyperkinetic extrapyramidal disorders remains uncertain.